Acute myeloid leukemia (AML) remains one of the most difficult blood cancers to treat. Although drug combinations are often more effective than single agents, their true mechanisms of action have been poorly understood. A new study published in Nature Communications introduces CoPISA—the Combinatorial Proteome Integral Solubility/Stability Alteration analysis, a powerful high-throughput proteomics workflow that uncovers how drug combinations reshape the soluble proteome in ways that single drugs cannot.
This article was originally published on MedicalXpress.com
